LifeMD Inc

AT&T has introduced Cricket 5G Home Internet, extending fixed wireless broadband over its existing 5G network for Cricket Wireless customers, and has partnered with LifeMD to give eligible AT&T subscribers free virtual healthcare visits and related telehealth services. The two moves widen AT&T's bundled connectivity offer by adding home broadband and healthcare benefits to its consumer plans, with the LifeMD benefits available to more than 100 million eligible customers. AT&T operates as a large US telecom provider with a market value of about $183.1b, and the company must fund the new perks while still managing heavy 5G and fiber spending and legacy revenue pressure. Analysts' forecasts assume 2.5% annual growth and a 13.4% margin, and the key commercial question is how many Cricket users bundle mobile and home service and what that does to churn. Investors will watch subscriber metrics over the next few quarters, especially Cricket 5G Home Internet adoption, uptake of LifeMD benefits, bundle penetration, fiber plus wireless households, and any disclosure on healthcare-driven engagement or reduced churn tied to AT&T's &More program.

AT&T Inc. has partnered with LifeMD, Inc. to give its eligible wireless and fiber customers complimentary access to virtual care and pharmacy services. Under the agreement, more than 100 million eligible AT&T customers will receive a LifeMD membership worth $228 annually, with the regular $19 monthly fee waived. The benefit is offered through AT&T's &More program, and customers must enroll to activate the complimentary membership, paying only for the visits, prescriptions, or other services they use. The rollout will initially cover about 29 million AT&T customers in 11 states and is expected to expand nationwide in January 2027. The initiative supports AT&T's efforts to broaden customer benefits and strengthen engagement as demand for telemedicine grows, amid competition from Verizon Communications, Inc. and T-Mobile US, Inc., which are advancing their own AI-powered and 5G healthcare offerings.

LifeMD reported second quarter 2026 revenue of $47.3 million, within its guidance range of $47 million to $50 million, and an adjusted EBITDA loss of approximately $3.5 million, a sequential improvement of about 21%. The company said approximately 95% of new weight management patients now start on branded GLP-1 therapies, marking the effective end of its transition away from compounded GLP-1 medications. Gross margin expanded roughly 280 basis points year-over-year to about 89%, driven by lower shipping and fulfillment costs and scaling of its in-house pharmacy. Weight Management Program subscribers grew to approximately 108,000, and total active subscribers rose 20% year-over-year to roughly 356,000. LifeMD also launched an exclusive telehealth co-marketing collaboration with Halozyme’s subsidiary Antares Pharma for XYOSTED, the only FDA-approved once-weekly subcutaneous testosterone auto-injector. The company exited the quarter with $25.1 million in cash, no debt, and $30 million of additional liquidity under its revolving credit facility. It expects a return to positive adjusted EBITDA in the second half of 2026 and a fourth-quarter exit revenue run rate of approximately $250 million with about $22 million of annualized adjusted EBITDA. Full-year 2026 guidance was revised to revenue of $205.5 million to $212.5 million and adjusted EBITDA of negative $6.0 million to breakeven, including $2 million to $3 million of net launch costs for XYOSTED.